Pulpotomy in caries-exposed immature permanent molars using calcium-enriched mixture cement or mineral trioxide aggregate: a randomized clinical trial.
OBJECTIVE
To compare clinical and radiographic outcomes of pulpotomy treatment using calcium-enriched mixture (CEM) cement and mineral trioxide aggregate (MTA) in carious-exposed vital immature permanent first molars.


METHODS
Fifty-one immature molars with clinical carious exposure with symptomatic/asymptomatic pulpitis met the inclusion criteria and randomly assigned to one of the treatment groups (CEM [26 teeth; 59 roots], MTA [25 teeth; 59 roots]). After performing pulpotomy and covering the radicular pulps with the biomaterials, all teeth were permanently restored. Blinded clinical and radiographic evaluations were performed at 6 and 12 months after operation for signs of success or failure. Radiographs were evaluated for complete/partial apical closure. The data were analysed using chi-square test and generalized estimating equation (GEE) model.


RESULTS
There was no significant difference at the baseline between the two experimental groups. All available cases (49 teeth) showed pulp survival and signs of continuous root development after 12 months. Overall, complete apical closure (apexogenesis) occurred in 76.8% and 73.8% of radiographically interpreted roots in CEM cement and MTA groups, respectively. There was no statistical difference in terms of radiographic outcomes between two groups.


CONCLUSIONS
Calcium-enriched mixture cement and MTA showed similar performance in pulpotomy of immature caries-exposed permanent molars.
Department of Endodontics, School of Dentistry, Rafsanjan University of Medical Sciences, Kerman, Iran. ansrt2@yahoo.com
Ali
A
Nosrat
Amir
A
Seifi
Saeed
S
Asgary
D017607:Aluminum Compounds / Q000627:therapeutic use; D056624:Apexification / Q000379:methods; D017610:Calcium Compounds / Q000627:therapeutic use; D002648:Child; D003731:Dental Caries / Q000628:therapy; D003782:Dental Pulp / Q000000981:diagnostic imaging / Q000187:drug effects; D003789:Dental Pulp Exposure / Q000628:therapy*; D003793:Dental Restoration, Permanent / Q000379:methods; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005899:Glass Ionomer Cements / Q000737:chemistry; D006801:Humans; D008297:Male; D008963:Molar / Q000187:drug effects / Q000473:pathology*; D009805:Odontogenesis / Q000187:drug effects; D010087:Oxides / Q000627:therapeutic use; D011446:Prospective Studies; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011672:Pulpotomy / Q000295:instrumentation / Q000379:methods*; D016300:Radiography, Bitewing; D017640:Silicates / Q000627:therapeutic use; D016037:Single-Blind Method; D019227:Tooth Apex / Q000187:drug effects / Q000473:pathology*; D014092:Tooth Root / Q000187:drug effects / Q000254:growth & development; D016896:Treatment Outcome
D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D005899:Glass Ionomer Cements; D010087:Oxides; D057872:Pulp Capping and Pulpectomy Agents; D017640:Silicates; C086631:mineral trioxide aggregate